A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2015-10

AUTHORS

Jun Ho Jang, Hironori Harada, Hirohiko Shibayama, Ryutaro Shimazaki, Hyeoung-Joon Kim, Kenichi Sawada, Kinuko Mitani

ABSTRACT

Darbepoetin alfa (DA) is a standard treatment for anemia in lower-risk MDS. However, to date there has been no comparative study to investigate the initial dosage. We, thus, conducted a randomized controlled trial to elucidate the optimal initial dosage of DA. International Prognostic Scoring System low or intermediate-1 risk MDS patients with hemoglobin levels ≤9.0 g/dL, serum erythropoietin levels ≤500 mIU/mL, and red blood cell transfusion dependency were enrolled. Patients were randomized to receive DA either at 60, 120, or 240 μg/week for 16 weeks followed by continuous administration with dose adjustment up to 48 weeks. Of 17, 18, and 15 patients in the 60, 120, and 240 μg DA groups included in the efficacy analysis, 64.7, 44.4, and 66.7 %, respectively, achieved the primary endpoint (major or minor erythroid response), while 17.6, 16.7, and 33.3 % achieved major erythroid responses in the initial 16-week period. No clinically significant safety concerns were identified. DA reduced the transfusion requirements effectively and safely in transfusion-dependent, lower-risk MDS patients. Given the highest achievement rate of the major erythroid response in the 240 μg group and the absence of dose-dependent adverse events, 240 μg weekly is the optimal initial dosage. More... »

PAGES

401-412

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12185-015-1862-5

DOI

http://dx.doi.org/10.1007/s12185-015-1862-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1025191030

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26323997


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Darbepoetin alfa", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Erythrocyte Transfusion", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myelodysplastic Syndromes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jang", 
        "givenName": "Jun Ho", 
        "id": "sg:person.0635513500.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635513500.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Juntendo University", 
          "id": "https://www.grid.ac/institutes/grid.258269.2", 
          "name": [
            "Department of Hematology and Oncology, Hiroshima University Hospital, Hiroshima, Japan", 
            "Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Harada", 
        "givenName": "Hironori", 
        "id": "sg:person.01126502475.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01126502475.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Osaka University", 
          "id": "https://www.grid.ac/institutes/grid.136593.b", 
          "name": [
            "Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shibayama", 
        "givenName": "Hirohiko", 
        "id": "sg:person.01273323113.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273323113.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kyowa Hakko Kirin (Japan)", 
          "id": "https://www.grid.ac/institutes/grid.473316.4", 
          "name": [
            "R&D Division, Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shimazaki", 
        "givenName": "Ryutaro", 
        "id": "sg:person.01305704201.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01305704201.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Chonnam National University Hwasun Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411602.0", 
          "name": [
            "Department of Hematology/Oncology, Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kim", 
        "givenName": "Hyeoung-Joon", 
        "id": "sg:person.0617770714.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617770714.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Akita University", 
          "id": "https://www.grid.ac/institutes/grid.251924.9", 
          "name": [
            "Akita University, Akita, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sawada", 
        "givenName": "Kenichi", 
        "id": "sg:person.0614414637.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614414637.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dokkyo Medical University", 
          "id": "https://www.grid.ac/institutes/grid.255137.7", 
          "name": [
            "Department of Hematology and Oncology, Dokkyo Medical University School of Medicine, 880, Kitakobayashi, Mibu-machi, Shimotsuga-gun, 321-0293, Tochigi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mitani", 
        "givenName": "Kinuko", 
        "id": "sg:person.01117236337.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117236337.14"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1111/j.1365-2141.2007.06546.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004811324"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1365-2141.1998.01085.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008861337"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/10428191003728610", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009375524"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdi400", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012099912"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdi400", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012099912"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1365-2141.2003.04153.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012572767"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2141.2008.07181.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013944855"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2009-03-211797", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019476660"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2009-03-211797", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019476660"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(03)14567-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019906916"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2141.2004.05288.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019926181"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.14.2885", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020174977"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2141.1995.tb08909.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024467708"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.12-10-1264", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026462072"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-008-0450-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026717109", 
          "https://doi.org/10.1007/s00277-008-0450-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-008-0450-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026717109", 
          "https://doi.org/10.1007/s00277-008-0450-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1185/03007995.2011.561834", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030966745"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2007-06-096370", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031702469"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.leukres.2010.05.030", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036408204"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2003-07-2252", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040095574"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1365-2141.1997.4013211.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040833966"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2012-03-420489", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042747172"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.22343", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043835071"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.15.4906", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044023105"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.06.150", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044791769"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.06.150", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044791769"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ajh.21316", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045670181"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2141.2006.06070.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046566146"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2013-07-512442", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048488834"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0145-2126(91)90025-o", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052668900"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/14712591003709713", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1067588099"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074587668", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077160478", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077232356", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077332500", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083056512", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-10", 
    "datePublishedReg": "2015-10-01", 
    "description": "Darbepoetin alfa (DA) is a standard treatment for anemia in lower-risk MDS. However, to date there has been no comparative study to investigate the initial dosage. We, thus, conducted a randomized controlled trial to elucidate the optimal initial dosage of DA. International Prognostic Scoring System low or intermediate-1 risk MDS patients with hemoglobin levels \u22649.0 g/dL, serum erythropoietin levels \u2264500 mIU/mL, and red blood cell transfusion dependency were enrolled. Patients were randomized to receive DA either at 60, 120, or 240 \u03bcg/week for 16 weeks followed by continuous administration with dose adjustment up to 48 weeks. Of 17, 18, and 15 patients in the 60, 120, and 240 \u03bcg DA groups included in the efficacy analysis, 64.7, 44.4, and 66.7 %, respectively, achieved the primary endpoint (major or minor erythroid response), while 17.6, 16.7, and 33.3 % achieved major erythroid responses in the initial 16-week period. No clinically significant safety concerns were identified. DA reduced the transfusion requirements effectively and safely in transfusion-dependent, lower-risk MDS patients. Given the highest achievement rate of the major erythroid response in the 240 \u03bcg group and the absence of dose-dependent adverse events, 240 \u03bcg weekly is the optimal initial dosage.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s12185-015-1862-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.5847960", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.6121672", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.6123606", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.5874923", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1076985", 
        "issn": [
          "0925-5710", 
          "1865-3774"
        ], 
        "name": "International Journal of Hematology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "102"
      }
    ], 
    "name": "A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes", 
    "pagination": "401-412", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "7802765ea9bbffe5d6b51774d94aceb8f791e43e5edc9019dc6895f0d64cfa80"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26323997"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9111627"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12185-015-1862-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1025191030"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12185-015-1862-5", 
      "https://app.dimensions.ai/details/publication/pub.1025191030"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T14:12", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8660_00000522.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs12185-015-1862-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12185-015-1862-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12185-015-1862-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12185-015-1862-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12185-015-1862-5'


 

This table displays all metadata directly associated to this object as RDF triples.

265 TRIPLES      21 PREDICATES      70 URIs      30 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12185-015-1862-5 schema:about N39bf3b910f7149c7a3da482b9f894f61
2 N5b9904447c7c4f2a8ac1569ea75a20a9
3 N6b2682352d18400fa1fd215a9a80eb51
4 Na2fca3506f61440eb0bf4e7662b42b64
5 Nb08c4b34eafb46fa801d85a14183e826
6 Nbd8872d895b84ac6b338f128bf4fca49
7 Ne5824d415018406db940d18caf7451e3
8 Ne7d6eaa4449343c28f163922a61475e3
9 Necbd592be53440b59089b4b0c5cf16c1
10 anzsrc-for:11
11 anzsrc-for:1103
12 schema:author N7dc591fdcf8245ea91634c7b6a999ae2
13 schema:citation sg:pub.10.1007/s00277-008-0450-7
14 https://app.dimensions.ai/details/publication/pub.1074587668
15 https://app.dimensions.ai/details/publication/pub.1077160478
16 https://app.dimensions.ai/details/publication/pub.1077232356
17 https://app.dimensions.ai/details/publication/pub.1077332500
18 https://app.dimensions.ai/details/publication/pub.1083056512
19 https://doi.org/10.1002/ajh.21316
20 https://doi.org/10.1002/cncr.22343
21 https://doi.org/10.1016/0145-2126(91)90025-o
22 https://doi.org/10.1016/j.leukres.2010.05.030
23 https://doi.org/10.1016/s0140-6736(03)14567-9
24 https://doi.org/10.1046/j.1365-2141.1997.4013211.x
25 https://doi.org/10.1046/j.1365-2141.1998.01085.x
26 https://doi.org/10.1046/j.1365-2141.2003.04153.x
27 https://doi.org/10.1093/annonc/mdi400
28 https://doi.org/10.1111/j.1365-2141.1995.tb08909.x
29 https://doi.org/10.1111/j.1365-2141.2004.05288.x
30 https://doi.org/10.1111/j.1365-2141.2006.06070.x
31 https://doi.org/10.1111/j.1365-2141.2007.06546.x
32 https://doi.org/10.1111/j.1365-2141.2008.07181.x
33 https://doi.org/10.1182/blood-2003-07-2252
34 https://doi.org/10.1182/blood-2007-06-096370
35 https://doi.org/10.1182/blood-2009-03-211797
36 https://doi.org/10.1182/blood-2012-03-420489
37 https://doi.org/10.1182/blood-2013-07-512442
38 https://doi.org/10.1185/03007995.2011.561834
39 https://doi.org/10.1200/jco.2005.06.150
40 https://doi.org/10.1200/jco.2007.14.2885
41 https://doi.org/10.1200/jco.2007.15.4906
42 https://doi.org/10.1517/14712591003709713
43 https://doi.org/10.1634/theoncologist.12-10-1264
44 https://doi.org/10.3109/10428191003728610
45 schema:datePublished 2015-10
46 schema:datePublishedReg 2015-10-01
47 schema:description Darbepoetin alfa (DA) is a standard treatment for anemia in lower-risk MDS. However, to date there has been no comparative study to investigate the initial dosage. We, thus, conducted a randomized controlled trial to elucidate the optimal initial dosage of DA. International Prognostic Scoring System low or intermediate-1 risk MDS patients with hemoglobin levels ≤9.0 g/dL, serum erythropoietin levels ≤500 mIU/mL, and red blood cell transfusion dependency were enrolled. Patients were randomized to receive DA either at 60, 120, or 240 μg/week for 16 weeks followed by continuous administration with dose adjustment up to 48 weeks. Of 17, 18, and 15 patients in the 60, 120, and 240 μg DA groups included in the efficacy analysis, 64.7, 44.4, and 66.7 %, respectively, achieved the primary endpoint (major or minor erythroid response), while 17.6, 16.7, and 33.3 % achieved major erythroid responses in the initial 16-week period. No clinically significant safety concerns were identified. DA reduced the transfusion requirements effectively and safely in transfusion-dependent, lower-risk MDS patients. Given the highest achievement rate of the major erythroid response in the 240 μg group and the absence of dose-dependent adverse events, 240 μg weekly is the optimal initial dosage.
48 schema:genre research_article
49 schema:inLanguage en
50 schema:isAccessibleForFree false
51 schema:isPartOf Ne917044c5bea479ca9016763ebb3930d
52 Neb467748474342f89261e80f9c4a1d8c
53 sg:journal.1076985
54 schema:name A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes
55 schema:pagination 401-412
56 schema:productId N25f28d98e716426eb53ed7092cc1fb6b
57 N56b05d343f70488c99334ea3162a2d1d
58 Nc34ae77342eb43488ea2de266dfec7a2
59 Nd5eb8c75c70e44aeab04a39206054180
60 Nf50efa6ddf5040b0b065d63261ba2d33
61 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025191030
62 https://doi.org/10.1007/s12185-015-1862-5
63 schema:sdDatePublished 2019-04-10T14:12
64 schema:sdLicense https://scigraph.springernature.com/explorer/license/
65 schema:sdPublisher Nf755cd18c27240c9be77634559a581c7
66 schema:url http://link.springer.com/10.1007%2Fs12185-015-1862-5
67 sgo:license sg:explorer/license/
68 sgo:sdDataset articles
69 rdf:type schema:ScholarlyArticle
70 N0fd72bf3705740748d163a8e1568dde3 rdf:first sg:person.01117236337.14
71 rdf:rest rdf:nil
72 N1528e9f727354143947b9158992ec555 rdf:first sg:person.0614414637.48
73 rdf:rest N0fd72bf3705740748d163a8e1568dde3
74 N25f28d98e716426eb53ed7092cc1fb6b schema:name nlm_unique_id
75 schema:value 9111627
76 rdf:type schema:PropertyValue
77 N39bf3b910f7149c7a3da482b9f894f61 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Humans
79 rdf:type schema:DefinedTerm
80 N42b02e0311694e16a86fd042fbf59348 rdf:first sg:person.01126502475.24
81 rdf:rest N59d9fff097af48ccb3f79e4482837ca3
82 N56b05d343f70488c99334ea3162a2d1d schema:name pubmed_id
83 schema:value 26323997
84 rdf:type schema:PropertyValue
85 N59d9fff097af48ccb3f79e4482837ca3 rdf:first sg:person.01273323113.98
86 rdf:rest N8497bec8fcab4df0a732b1cd687f04ac
87 N5b9904447c7c4f2a8ac1569ea75a20a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Aged
89 rdf:type schema:DefinedTerm
90 N618267b3e6514daf8997835679e0a156 rdf:first sg:person.0617770714.19
91 rdf:rest N1528e9f727354143947b9158992ec555
92 N6b2682352d18400fa1fd215a9a80eb51 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Middle Aged
94 rdf:type schema:DefinedTerm
95 N7dc591fdcf8245ea91634c7b6a999ae2 rdf:first sg:person.0635513500.34
96 rdf:rest N42b02e0311694e16a86fd042fbf59348
97 N8497bec8fcab4df0a732b1cd687f04ac rdf:first sg:person.01305704201.18
98 rdf:rest N618267b3e6514daf8997835679e0a156
99 Na2fca3506f61440eb0bf4e7662b42b64 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Erythrocyte Transfusion
101 rdf:type schema:DefinedTerm
102 Nb08c4b34eafb46fa801d85a14183e826 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Dose-Response Relationship, Drug
104 rdf:type schema:DefinedTerm
105 Nb956626d2ac446459a87476477849abd schema:name Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
106 rdf:type schema:Organization
107 Nbd8872d895b84ac6b338f128bf4fca49 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Darbepoetin alfa
109 rdf:type schema:DefinedTerm
110 Nc34ae77342eb43488ea2de266dfec7a2 schema:name dimensions_id
111 schema:value pub.1025191030
112 rdf:type schema:PropertyValue
113 Nd5eb8c75c70e44aeab04a39206054180 schema:name doi
114 schema:value 10.1007/s12185-015-1862-5
115 rdf:type schema:PropertyValue
116 Ne5824d415018406db940d18caf7451e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Risk Factors
118 rdf:type schema:DefinedTerm
119 Ne7d6eaa4449343c28f163922a61475e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Myelodysplastic Syndromes
121 rdf:type schema:DefinedTerm
122 Ne917044c5bea479ca9016763ebb3930d schema:volumeNumber 102
123 rdf:type schema:PublicationVolume
124 Neb467748474342f89261e80f9c4a1d8c schema:issueNumber 4
125 rdf:type schema:PublicationIssue
126 Necbd592be53440b59089b4b0c5cf16c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Aged, 80 and over
128 rdf:type schema:DefinedTerm
129 Nf50efa6ddf5040b0b065d63261ba2d33 schema:name readcube_id
130 schema:value 7802765ea9bbffe5d6b51774d94aceb8f791e43e5edc9019dc6895f0d64cfa80
131 rdf:type schema:PropertyValue
132 Nf755cd18c27240c9be77634559a581c7 schema:name Springer Nature - SN SciGraph project
133 rdf:type schema:Organization
134 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
135 schema:name Medical and Health Sciences
136 rdf:type schema:DefinedTerm
137 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
138 schema:name Clinical Sciences
139 rdf:type schema:DefinedTerm
140 sg:grant.5847960 http://pending.schema.org/fundedItem sg:pub.10.1007/s12185-015-1862-5
141 rdf:type schema:MonetaryGrant
142 sg:grant.5874923 http://pending.schema.org/fundedItem sg:pub.10.1007/s12185-015-1862-5
143 rdf:type schema:MonetaryGrant
144 sg:grant.6121672 http://pending.schema.org/fundedItem sg:pub.10.1007/s12185-015-1862-5
145 rdf:type schema:MonetaryGrant
146 sg:grant.6123606 http://pending.schema.org/fundedItem sg:pub.10.1007/s12185-015-1862-5
147 rdf:type schema:MonetaryGrant
148 sg:journal.1076985 schema:issn 0925-5710
149 1865-3774
150 schema:name International Journal of Hematology
151 rdf:type schema:Periodical
152 sg:person.01117236337.14 schema:affiliation https://www.grid.ac/institutes/grid.255137.7
153 schema:familyName Mitani
154 schema:givenName Kinuko
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117236337.14
156 rdf:type schema:Person
157 sg:person.01126502475.24 schema:affiliation https://www.grid.ac/institutes/grid.258269.2
158 schema:familyName Harada
159 schema:givenName Hironori
160 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01126502475.24
161 rdf:type schema:Person
162 sg:person.01273323113.98 schema:affiliation https://www.grid.ac/institutes/grid.136593.b
163 schema:familyName Shibayama
164 schema:givenName Hirohiko
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273323113.98
166 rdf:type schema:Person
167 sg:person.01305704201.18 schema:affiliation https://www.grid.ac/institutes/grid.473316.4
168 schema:familyName Shimazaki
169 schema:givenName Ryutaro
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01305704201.18
171 rdf:type schema:Person
172 sg:person.0614414637.48 schema:affiliation https://www.grid.ac/institutes/grid.251924.9
173 schema:familyName Sawada
174 schema:givenName Kenichi
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614414637.48
176 rdf:type schema:Person
177 sg:person.0617770714.19 schema:affiliation https://www.grid.ac/institutes/grid.411602.0
178 schema:familyName Kim
179 schema:givenName Hyeoung-Joon
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617770714.19
181 rdf:type schema:Person
182 sg:person.0635513500.34 schema:affiliation Nb956626d2ac446459a87476477849abd
183 schema:familyName Jang
184 schema:givenName Jun Ho
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635513500.34
186 rdf:type schema:Person
187 sg:pub.10.1007/s00277-008-0450-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026717109
188 https://doi.org/10.1007/s00277-008-0450-7
189 rdf:type schema:CreativeWork
190 https://app.dimensions.ai/details/publication/pub.1074587668 schema:CreativeWork
191 https://app.dimensions.ai/details/publication/pub.1077160478 schema:CreativeWork
192 https://app.dimensions.ai/details/publication/pub.1077232356 schema:CreativeWork
193 https://app.dimensions.ai/details/publication/pub.1077332500 schema:CreativeWork
194 https://app.dimensions.ai/details/publication/pub.1083056512 schema:CreativeWork
195 https://doi.org/10.1002/ajh.21316 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045670181
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1002/cncr.22343 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043835071
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1016/0145-2126(91)90025-o schema:sameAs https://app.dimensions.ai/details/publication/pub.1052668900
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1016/j.leukres.2010.05.030 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036408204
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1016/s0140-6736(03)14567-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019906916
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1046/j.1365-2141.1997.4013211.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1040833966
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1046/j.1365-2141.1998.01085.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1008861337
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1046/j.1365-2141.2003.04153.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1012572767
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1093/annonc/mdi400 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012099912
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1111/j.1365-2141.1995.tb08909.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1024467708
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1111/j.1365-2141.2004.05288.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1019926181
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1111/j.1365-2141.2006.06070.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1046566146
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1111/j.1365-2141.2007.06546.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1004811324
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1111/j.1365-2141.2008.07181.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1013944855
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1182/blood-2003-07-2252 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040095574
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1182/blood-2007-06-096370 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031702469
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1182/blood-2009-03-211797 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019476660
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1182/blood-2012-03-420489 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042747172
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1182/blood-2013-07-512442 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048488834
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1185/03007995.2011.561834 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030966745
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1200/jco.2005.06.150 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044791769
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1200/jco.2007.14.2885 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020174977
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1200/jco.2007.15.4906 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044023105
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1517/14712591003709713 schema:sameAs https://app.dimensions.ai/details/publication/pub.1067588099
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1634/theoncologist.12-10-1264 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026462072
244 rdf:type schema:CreativeWork
245 https://doi.org/10.3109/10428191003728610 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009375524
246 rdf:type schema:CreativeWork
247 https://www.grid.ac/institutes/grid.136593.b schema:alternateName Osaka University
248 schema:name Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan
249 rdf:type schema:Organization
250 https://www.grid.ac/institutes/grid.251924.9 schema:alternateName Akita University
251 schema:name Akita University, Akita, Japan
252 rdf:type schema:Organization
253 https://www.grid.ac/institutes/grid.255137.7 schema:alternateName Dokkyo Medical University
254 schema:name Department of Hematology and Oncology, Dokkyo Medical University School of Medicine, 880, Kitakobayashi, Mibu-machi, Shimotsuga-gun, 321-0293, Tochigi, Japan
255 rdf:type schema:Organization
256 https://www.grid.ac/institutes/grid.258269.2 schema:alternateName Juntendo University
257 schema:name Department of Hematology and Oncology, Hiroshima University Hospital, Hiroshima, Japan
258 Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan
259 rdf:type schema:Organization
260 https://www.grid.ac/institutes/grid.411602.0 schema:alternateName Chonnam National University Hwasun Hospital
261 schema:name Department of Hematology/Oncology, Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, Korea
262 rdf:type schema:Organization
263 https://www.grid.ac/institutes/grid.473316.4 schema:alternateName Kyowa Hakko Kirin (Japan)
264 schema:name R&D Division, Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan
265 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...